<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762474</url>
  </required_header>
  <id_info>
    <org_study_id>ESO20140703</org_study_id>
    <nct_id>NCT02762474</nct_id>
  </id_info>
  <brief_title>Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer</brief_title>
  <official_title>A Phase I/II Trial of Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT for Inoperable,Locally Advanced Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is going to evaluate the efficacy and safety of IMRT / nab-TP chemotherapy for
      unresectable esophageal cancer, and to investigate the optimal concurrent chemotherapy
      regimen for local advanced and unresectable esophageal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal carcinoma is the sixth leading cause of cancer-related mortality from cancer with
      407000 deaths and the eighth most common cancer worldwide. Concurrent chemoradiotherapy
      remains the mainstay of treatment for locally advanced esophageal cancer. Paclitaxel combined
      with radiotherapy was high efficiency and achieved encouraging results. Compared with
      paclitaxel, nab-paclitaxel has a low toxicity, low allergy and the tolerance is better than
      paclitaxel. According to the pre-clinical results, investigators designed a prospective
      study, which is combined nab-paclitaxel and cisplatin with concurrent chemoradiotherapy for
      the patients with locally advanced esophageal cancer, and evaluated the tolerability and
      efficacy. we design enrolled 30 patients, the end point included toxicity, progression-free
      survival and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTCAE 4.0 toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel group</intervention_name>
    <description>Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT</description>
    <arm_group_label>nab-paclitaxel group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. inoperable locally advanced histologically confirmed esophageal cancer
             (T3N0M0-TxNxM1a（AJCC 2002)

          2. ECOG performance status scale 0-1

          3. at least 1 measurable target lesions

          4. white blood count ≥ 3,500/mm3, absolute neutrophil count ≥ 1,500/mm3, platelet count ≥
             100,000/mm3, hemoglobin count ≥ 90 g/dL, serum bilirubin level &lt; 1.5 of the upper
             limit of normal (ULN) for the institution, aspartate aminotransferase, alanine
             aminotransferase and alkaline phosphatase ≤ 2.5 ULN, serum albumin ≥ 30g/L, serum
             creatinine ≤ 1.5 ULN; and

          5. normal cardiac function with no severe heart disease.

        Exclusion Criteria:

          1. history of esophagectomy

          2. pregnancy or breast feeding

          3. past history of other cancers except for cured non-melanoma skin cancer or cervical
             cancer;

          4. concomitant treatment with other anticancer drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Wang, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Wang, M. D.</last_name>
    <phone>0862223340123</phone>
    <email>wangping@tjmuch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Wang, M. D.</last_name>
    <email>wangping@tjmuch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Wang, M. D.</last_name>
      <phone>08623340123-1141</phone>
      <email>wangping@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nab-paclitaxel</keyword>
  <keyword>IMRT</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

